Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Start-Ups Target A Place At Global Top Table, But Must Avoid The Ten Major Errors

Executive Summary

France’s medtech industry association, Snitem, says everything is in place to create a globally-leading start-ups sector locally, but all stakeholders must play their part, and companies should be wary of falling into easy traps.

You may also be interested in...



MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

French Minister Has Her Own Angle On the Success Of Medtech

The 5th annual journée start-up innovantes du dispositif médical was officially opened by French secretary of state Agnès Pannier-Runacher, who has first-hand experience of the benefits of health-tech innovation. She listed the challenges that innovative start-ups must surmount.

MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance

26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT125425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel